Trial for Alterity’s neurodegenerative drug ATH434 shows reduced disability
Alterity Therapeutics Ltd (ASX:ATH) has reported positive interim results from its Phase…
Alterity Therapeutics Limited (ASX:ATH)
About Alterity Therapeutics Limited
Key Information
ATH In the News
ASX Announcements
| Date | Announcement | File | Views |
|---|---|---|---|
| 24/07/2024 | Alterity Therapeutics to Present at MST Financial Webinar | 158.86KB | 950 |
| 19/07/2024 | Notice Under Section 708A | 230.29KB | 987 |
| 19/07/2024 | Application for quotation of securities - ATH | 15.69KB | 263 |
| 18/07/2024 | Proposed issue of securities - ATH | 15.09KB | 658 |
| 17/07/2024 | Price Sensitive PS Positive Interim Data from ATH434-202 Phase 2 Clinical Trial | 261.82KB | 39K |
| 15/07/2024 | Price Sensitive PS Trading Halt | 215.69KB | 22K |
| 28/06/2024 | Notification regarding unquoted securities - ATH | 23.53KB | 373 |
| 13/06/2024 | Alterity to Present at Hidden Gems in Life Sciences Webinar | 160.16KB | 5.8K |